Viagra in China: Prolonged Battle over Intellectual Property Rights Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

In April of 1998, Pfizer Inc ("Pfizer") launched Viagra, a drug used to treat erectile dysfunction in the U.S. and Europe with great success. However, its time to market of China, met the 11-year battle with local pharmaceutical companies over patent for Viagra, the Chinese trademarks and trademarks dimensional ("3D trade mark"). Pfizer Patent was invalid in July 2004 after the authorities together contested by 12 local companies. local company has launched its own drug erectile dysfunction with Chinese nickname for Viagra as its trademark and brand name Viagra 3D copy. Pfizer defended its intellectual property rights ("IPR") in court. He won the patent and trademark 3D characters trials, but lost the case in the Chinese trademark. Whatever the outcome of the judicial sale of Viagra in China were smothered widespread fraud and herbal substitutes containing the active substance or its equivalent. management company Pfizer is trying to figure out what went wrong in its market strategy out how to make more sales before its patent expires in 2014, and what should be done to better protect intellectual property rights, it plans to launch products in the country. "Hide
on Yahong Li, Jiangyong Lu, Zhigang Tao, Shangjin Wei, Penelope Chan Source: University of Hong Kong, 32 pages. Publication Date: June 29, 2010. Prod. #: HKU902-PDF-ENG